Post-HSCT COVID-19 Vaccination in Resource-Limited Settings: Why Adaptation Should Not Mean Compromise
Abstract
Post-HSCT COVID-19 Vaccination in Resource-Limited Settings: Why Adaptation Should Not Mean Compromise
1. European Society for Blood and Marrow Transplantation. COVID-19 and BMT: EBMT recommendations update. https://www.ebmt.org/covid-19-and-bmt (2024).
2. American Society of Hematology, American Society for Transplantation and Cellular Therapy. COVID-19 vaccination for HCT and CAR T-cell recipients. https://www.hematology.org/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients (2022).
3. National Comprehensive Cancer Network. Prevention and Treatment of Cancer-Related Infections. NCCN Clinical Practice Guidelines in Oncology, Version 1.2026.
https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1457.
4. Barkhordar M, Chahardouli B, Biglari M, et al. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response—a prospective, single-arm study. Front Immunol. 2023:14:1169666.
5. Barkhordar M, Ahmadvand M, Sharifi Aliabadi L, et al. Evaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial. Vaccines (Basel). 2023;11(1):117.
6. Sharifi Aliabadi L, Karami M, Barkhordar M, et al. Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial. Front Immunol. 2023:14:1237916.
7. Sharifi Aliabadi L, Azari M, Taherian MR, et al. Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis. Virol J. 2024; 21(1): 103.
8. Mousavi SA, Rad S, Rostami T, et al. Guidance for Facing Dilemmas of Hematopoietic Stem Cell Transplant Clinicians in the COVID-19 Pandemic: An Iranian Consensus. Mediterr J Hematol Infect Dis. 2020;12(1):e2020050.
9. Saleh M, Vaezi AA, Sohrabpour AA, et al. Wharton's jelly-mesenchymal stem cells treatment for severe COVID-19 patients: 1-year follow-up. Gene Rep. 2022; 29: 101691.
2. American Society of Hematology, American Society for Transplantation and Cellular Therapy. COVID-19 vaccination for HCT and CAR T-cell recipients. https://www.hematology.org/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients (2022).
3. National Comprehensive Cancer Network. Prevention and Treatment of Cancer-Related Infections. NCCN Clinical Practice Guidelines in Oncology, Version 1.2026.
https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1457.
4. Barkhordar M, Chahardouli B, Biglari M, et al. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response—a prospective, single-arm study. Front Immunol. 2023:14:1169666.
5. Barkhordar M, Ahmadvand M, Sharifi Aliabadi L, et al. Evaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial. Vaccines (Basel). 2023;11(1):117.
6. Sharifi Aliabadi L, Karami M, Barkhordar M, et al. Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial. Front Immunol. 2023:14:1237916.
7. Sharifi Aliabadi L, Azari M, Taherian MR, et al. Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis. Virol J. 2024; 21(1): 103.
8. Mousavi SA, Rad S, Rostami T, et al. Guidance for Facing Dilemmas of Hematopoietic Stem Cell Transplant Clinicians in the COVID-19 Pandemic: An Iranian Consensus. Mediterr J Hematol Infect Dis. 2020;12(1):e2020050.
9. Saleh M, Vaezi AA, Sohrabpour AA, et al. Wharton's jelly-mesenchymal stem cells treatment for severe COVID-19 patients: 1-year follow-up. Gene Rep. 2022; 29: 101691.
| Files | ||
| Issue | Vol 20 No 2 (2026) | |
| Section | Editorial | |
| Keywords | ||
| HSCT; COVID-19 vaccination; Allogeneic transplantation; Autologous transplantation; Booster dose; Heterologous; Vaccination; Resource-limited settings; Iran | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Barkhordar M. Post-HSCT COVID-19 Vaccination in Resource-Limited Settings: Why Adaptation Should Not Mean Compromise. Int J Hematol Oncol Stem Cell Res. 2026;20(2):221-225.
